Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | KHK | P50053 | 2/20 | 0.45 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139207 | 1.00 | MAPT (0.46) | MAPTNOTUMKHKCSNK1EKDM4E | |
| SCHEMBL3612506 | 1.00 | MAPT (0.46) | MAPTNOTUMKHKCSNK1EKDM4E | |
| Hydrochloric Acid SCHEMBL15848166 | 0.98 | MAPT (0.45) | MAPTNOTUMKHKCSNK1EKDM4E | |
| SCHEMBL2246734 | 0.95 | CSNK1E (0.46) | MAPTNOTUMKHKCSNK1EKDM4E | |
| SCHEMBL5272469 | 0.95 | CSNK1E (0.46) | MAPTNOTUMKHKCSNK1EKDM4E | |
| SCHEMBL6811911 | 0.84 | MAPT (0.46) | MAPTKHKCSNK1EBCL2A1ALDH1A1 | |
| SCHEMBL24123867 | 0.84 | ADRB1 (0.58) | MAPTKHKBCL2A1ALDH1A1LMNA | |
| SCHEMBL6786862 | 0.84 | ADRB1 (0.58) | MAPTKHKBCL2A1ALDH1A1LMNA | |
| SCHEMBL2245943 | 0.84 | ADRB1 (0.58) | MAPTKHKBCL2A1ALDH1A1LMNA | |
| SCHEMBL1203357 | 0.82 | HTR3E (0.56) | MAPTNOTUMKHKBCL2A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106459067-B | For treating -1 yl-benzamide compound of imidazo [1,2-A] pyrazine of Duchenne-Arandisease | 豪夫迈·罗氏有限公司 | 2019-05-31 | — | — | CN | claimed |
| CN-114945575-B | Novel functionalized lactones as modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2024-09-03 | — | — | CN | disclosed |
| US-20230025932-A1 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-05 | — | — | US | disclosed |
| EP-4058458-A2 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-4058455-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115003675-A | Novel functionalized lactams as 5-hydroxytryptamine receptor 7 modulators and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-114945575-A | Novel functionalized lactones as 5-hydroxytryptamine receptor 7 modulators and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2022-08-26 | — | — | CN | disclosed |
| WO-2021097116-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-2938344-B1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| CN-101124213-A | Sulfonylamino cyclic derivatives and uses thereof | SERONO LAB (CH) | 2008-02-13 | — | — | CN | disclosed |
| EP-1828160-A1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| WO-2007070506-A2 | DIAZA HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2006067114-A1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | GLP1R, GPR119, INSR | MAPT 4781/4885NOTUM 3031/4885KHK 1650/4885 |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | GLS2, SRM, GLS | MAPT 4423/4885NOTUM 1676/4885KHK 1785/4885 |
| US-20230025932-A1 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, HTR3A | MAPT 3514/4885NOTUM 913/4885KHK 3508/4885 |
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR1A, HTR2C | MAPT 3153/4885NOTUM 986/4885KHK 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.